<!doctype html><html lang=en><head><meta charset=utf-8><meta name=description content="bevacizumab Avastin®；癌思停®注射劑。
轉移性大腸直腸癌(mCRC) Avastin®(bevacizumab) 與含有5-fluorouracil為基礎的化學療法合併使用，可以作為轉移性大腸或直腸癌病人的第一線治療。
Avastin®與含有5-fluorouracil/leucovorin/oxaliplatin的化學療法合併使用，可以作為先前接受過以fluoropyrimidine為基礎的化學療法無效且未曾接受過Avastin®治療的轉移性大腸或直腸癌病人的治療。
Avastin (bevacizumab)與含有fluoropyrimidine-irinotecan-或fluoropyrimidine-oxaliplatin-為基礎的化學療法合併使用，可以做為第一線已接受過以Avastin 併用化療後惡化之轉移性大腸或直腸癌病人的第二線治療。
說明: Avastin (bevacizumab) 不適用於高風險的二期以及三期大腸癌輔助性療法 (high risk stage II and III adjuvant colon cancer; aCC)"><title>bevacizumab</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://htlin222.github.io/garden//icon.png><link href=https://htlin222.github.io/garden/styles.547fb332ce56cdc523146ba5ede80d7f.min.css rel=stylesheet><link href=https://htlin222.github.io/garden/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://htlin222.github.io/garden/js/darkmode.f852e6b434606ed577a6f145a9173070.min.js></script>
<script src=https://htlin222.github.io/garden/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://htlin222.github.io/garden/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://htlin222.github.io/garden/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://htlin222.github.io/garden/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://htlin222.github.io/garden/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://htlin222.github.io/garden/",fetchData=Promise.all([fetch("https://htlin222.github.io/garden/indices/linkIndex.713f53b3fe7bb6a4a1b2463e81400128.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://htlin222.github.io/garden/indices/contentIndex.5026f7c90a7130b79caeeb4be323dbad.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://htlin222.github.io/garden",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://htlin222.github.io/garden",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/htlin222.github.io\/garden\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=Search placeholder="Search for something..."><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://htlin222.github.io/garden/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://htlin222.github.io/garden/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>Search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">Search Icon</title><desc id="desc">Icon to open search</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Light Mode</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>Dark Mode</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>bevacizumab</h1><p class=meta>Last updated
Jan 9, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/bevacizumab.md rel=noopener>Edit Source</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>Table of Contents</summary><nav id=TableOfContents><ol><li><a href=#轉移性大腸直腸癌mcrc>轉移性大腸直腸癌(mCRC)</a></li><li><a href=#轉移性乳癌mbc>轉移性乳癌(mBC)</a></li><li><a href=#惡性神經膠質瘤who第4級---神經膠母細胞瘤>惡性神經膠質瘤(WHO第4級) - 神經膠母細胞瘤</a></li><li><a href=#晚期轉移性或復發性非鱗狀非小細胞肺癌-nsclc>晚期、轉移性或復發性非鱗狀非小細胞肺癌 (NSCLC)</a></li><li><a href=#卵巢上皮細胞輸卵管或原發性腹膜癌epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer>卵巢上皮細胞、輸卵管或原發性腹膜癌(Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer)</a></li><li><a href=#持續性復發性或轉移性之子宮頸癌--persistent-recurrent-or-metastatic-cervical-cancer>持續性、復發性或轉移性之子宮頸癌 (Persistent, Recurrent, or Metastatic Cervical Cancer)</a></li></ol></nav></details></aside><a href=#bevacizumab><h1 id=bevacizumab><span class=hanchor arialabel=Anchor># </span>bevacizumab</h1></a><p>Avastin®；癌思停®注射劑。</p><a href=#轉移性大腸直腸癌mcrc><h2 id=轉移性大腸直腸癌mcrc><span class=hanchor arialabel=Anchor># </span>轉移性大腸直腸癌(mCRC)</h2></a><p>Avastin®(bevacizumab) 與含有5-fluorouracil為基礎的化學療法合併使用，可以作為轉移性大腸或直腸癌病人的第一線治療。</p><p>Avastin®與含有5-fluorouracil/leucovorin/oxaliplatin的化學療法合併使用，可以作為先前接受過以fluoropyrimidine為基礎的化學療法無效且未曾接受過Avastin®治療的轉移性大腸或直腸癌病人的治療。</p><p>Avastin (bevacizumab)與含有fluoropyrimidine-irinotecan-或fluoropyrimidine-oxaliplatin-為基礎的化學療法合併使用，可以做為第一線已接受過以Avastin 併用化療後惡化之轉移性大腸或直腸癌病人的第二線治療。</p><p>說明: Avastin (bevacizumab) 不適用於高風險的二期以及三期大腸癌輔助性療法 (high risk stage II and III adjuvant colon cancer; aCC)</p><a href=#轉移性乳癌mbc><h2 id=轉移性乳癌mbc><span class=hanchor arialabel=Anchor># </span>轉移性乳癌(mBC)</h2></a><p>Avastin®與paclitaxel合併使用，可以做為HER2 (-) 轉移性乳癌病人的第一線治療。</p><p>說明：</p><ol><li><p>Avastin®與paclitaxel併用在治療轉移性乳癌病人之療效，僅在無疾病進展存活期方面可達統計上顯著優於paclitaxel單獨使用，目前並無以整體存活期為主要療效指標之臨床試驗證實Avastin®與paclitaxel併用延長整體存活期之效果。</p></li><li><p>Avastin®不適用於經anthracycline及taxane治療轉移性乳癌又出現疾病進展的病人。</p></li></ol><a href=#惡性神經膠質瘤who第4級---神經膠母細胞瘤><h2 id=惡性神經膠質瘤who第4級---神經膠母細胞瘤><span class=hanchor arialabel=Anchor># </span>惡性神經膠質瘤(WHO第4級) - 神經膠母細胞瘤</h2></a><p>Avastin®單獨使用可用於治療曾接受標準放射線治療且含Temozolomide 在內之化學藥物治療失敗之多型性神經膠母細胞瘤(Glioblastoma multiforme)復發之成人病人。</p><a href=#晚期轉移性或復發性非鱗狀非小細胞肺癌-nsclc><h2 id=晚期轉移性或復發性非鱗狀非小細胞肺癌-nsclc><span class=hanchor arialabel=Anchor># </span>晚期、轉移性或復發性非鱗狀非小細胞肺癌 (NSCLC)</h2></a><p>Avastin®與carboplatin及paclitaxel合併使用，可以作為無法切除的晚期、轉移性或復發性非鱗狀非小細胞肺癌病人的第一線治療。</p><p>Avastin併用erlotinib，可作為無法手術切除的晚期、轉移性或復發性且帶有表皮生長因子受體(EGFR)活化性突變的非鱗狀非小細胞肺癌病人的第一線治療。</p><a href=#卵巢上皮細胞輸卵管或原發性腹膜癌epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer><h2 id=卵巢上皮細胞輸卵管或原發性腹膜癌epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer><span class=hanchor arialabel=Anchor># </span>卵巢上皮細胞、輸卵管或原發性腹膜癌(Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer)</h2></a><p>Avastin與carboplatin及paclitaxel合併使用，接著單獨使用Avastin，可以做為第三期或第四期卵巢上皮細胞、輸卵管或原發性腹膜癌病人接受初次手術切除後之治療。</p><p>Avastin與carboplatin及gemcitabine合併使用，可以做為曾接受過第一線含鉑類藥物 (Platinum-based) 化學治療間隔至少6個月再復發 (即，對含鉑藥物具感受性)，且未曾接受過bevacizumab或其他血管內皮細胞生長因子 (VEGF) 抑制劑或血管內皮細胞生長因子接受器之標靶藥物 (VEGF receptor-targeted agents) 治療之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人之治療。</p><p>Avastin與carboplatin及paclitaxel合併使用，接著單獨使用Avastin治療，可以做為對含鉑藥物具感受性之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。</p><p>Avastin併用paclitaxel、topotecan或pegylated liposomal doxorubicin 可以做為接受過含鉑類藥物 (platinum-based) 化療治療後6個月內再復發 (即，對含鉑藥物具抗藥性)、之前接受不超過2種化療療程且未曾接受過bevacizumab或其他血管內皮細胞生長因子 (VEGF)抑制劑或血管內皮細胞生長因子接受器之標靶藥物 (VEGF receptor-targeted agents) 之復發性卵巢上皮細胞、輸卵管或原發性腹膜癌病人的治療。</p><a href=#持續性復發性或轉移性之子宮頸癌--persistent-recurrent-or-metastatic-cervical-cancer><h2 id=持續性復發性或轉移性之子宮頸癌--persistent-recurrent-or-metastatic-cervical-cancer><span class=hanchor arialabel=Anchor># </span>持續性、復發性或轉移性之子宮頸癌 (Persistent, Recurrent, or Metastatic Cervical Cancer)</h2></a><p>Avastin與paclitaxel及cisplatin 合併使用可用於治療持續性、復發性或轉移性之子宮頸癌。Avastin 與paclitaxel 及topotecan 合併使用可用於無法接受含鉑類藥物治療(platinum therapy) 病人之持續性、復發性或轉移性子宮頸癌。</p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>Backlinks</h3><ul class=backlinks><li><a href=/garden/Adeno-or-Other-in-Stage-IV-NSCLC-Treatment/ data-ctx=bevacizumab data-src=/Adeno-or-Other-in-Stage-IV-NSCLC-Treatment class=internal-link>Adeno or Other in Stage IV NSCLC Treatment</a></li><li><a href=/garden/hepatocellular-carcinoma/ data-ctx=bevacizumab data-src=/hepatocellular-carcinoma class=internal-link>hepatocellular carcinoma</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>Interactive Graph</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://htlin222.github.io/garden/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div id=contact_buttons><footer><p>Made by Hsieh-Ting Lin using <a href=https://github.com/jackyzha0/quartz>Quartz</a>, © 2023</p><ul><li><a href=https://htlin222.github.io/garden/>Home</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li></ul></footer></div></div></body></html>